PTJ
RARE icon

Paul Tudor Jones’s Ultragenyx Pharmaceutical RARE Stock Holding History

Paul Tudor Jones’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-53,517
Closed -$1.12M – 4145
2026
Q1 		$1.12M Buy
53,517
+40,101
+299% +$903K ﹤0.01% 2284
2025
Q4 		$309K Sell
13,416
-45,862
-77% -$1.51M ﹤0.01% 3029
2025
Q3 		$1.78M Buy
59,278
+6,139
+12% +$184K ﹤0.01% 1877
2025
Q2 		$1.93M Buy
53,139
+30,665
+136% +$1.11M ﹤0.01% 1688
2025
Q1 		$814K Buy
+22,474
New +$935K ﹤0.01% 1949
2024
Q4 		– Sell
-54,496
Closed -$3.03M – 3418
2024
Q3 		$3.03M Buy
54,496
+19,933
+58% +$1.02M 0.01% 969
2024
Q2 		$1.42M Buy
+34,563
New +$1.48M 0.01% 1269
2023
Q3 		– Sell
-36,919
Closed -$1.7M – 2760
2023
Q2 		$1.7M Sell
36,919
-548
-1% -$25.4K 0.02% 979
2023
Q1 		$1.5M Buy
+37,467
New +$1.61M 0.02% 955
2022
Q4 		– Sell
-35,729
Closed -$1.48M – 2773
2022
Q3 		$1.48M Buy
35,729
+19,338
+118% +$994K 0.03% 674
2022
Q2 		$978K Buy
+16,391
New +$1.01M 0.03% 898
2022
Q1 		– Sell
-4,430
Closed -$373K – 2554
2021
Q4 		$373K Sell
4,430
-31,359
-88% -$2.55M 0.01% 1685
2021
Q3 		$3.23M Buy
35,789
+19,932
+126% +$1.8M 0.05% 444
2021
Q2 		$1.51M Buy
+15,857
New +$1.65M 0.03% 677
2021
Q1 		– Sell
-17,712
Closed -$2.45M – 1800
2020
Q4 		$2.45M Buy
17,712
+1,727
+11% +$205K 0.07% 342
2020
Q3 		$1.31M Buy
15,985
+5,318
+50% +$441K 0.06% 471
2020
Q2 		$834K Buy
+10,667
New +$706K 0.04% 534
2019
Q4 		– Sell
-14,214
Closed -$608K – 1342
2019
Q3 		$608K Buy
+14,214
New +$772K 0.02% 654
2017
Q2 		– Sell
-6,343
Closed -$430K – 1314
2017
Q1 		$430K Buy
+6,343
New +$483K 0.01% 768
2015
Q4 		– Sell
-2,441
Closed -$235K – 1797
2015
Q3 		$235K Buy
+2,441
New +$279K 0.01% 1244

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Paul Tudor Jones's RARE Position: Q2 2026 in Review

Paul Tudor Jones sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2026, closing a stake of 53,517 shares — an estimated $1.12M sold.

Paul Tudor Jones first reported a position in RARE in Q3 2015 and held it in 20 quarters. The position peaked at $3.23M in Q3 2021. 308 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Paul Tudor Jones reported no remaining Ultragenyx Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • Paul Tudor Jones sold 53,517 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $1.12M.
  • Paul Tudor Jones first reported a position in Ultragenyx Pharmaceutical in Q3 2015 and held it in 20 quarters.
  • Paul Tudor Jones's Ultragenyx Pharmaceutical position peaked at $3.23M in Q3 2021.
  • 308 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.